Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1988 1
2008 1
2014 1
2015 1
2020 5
2021 12
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
Your search for Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe D retrieved no results
Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
Ricke DO. Ricke DO. Front Immunol. 2021 Feb 24;12:640093. doi: 10.3389/fimmu.2021.640093. eCollection 2021. Front Immunol. 2021. PMID: 33717193 Free PMC article.
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-like symptoms, moderate, severe, critical, and chronic disease. ...Development of vaccines to severe acute respiratory syndrome (SARS), Middle East Respi …
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-like symptoms, moderate, severe
Kinetics of viral load and antibody response in relation to COVID-19 severity.
Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, Song T, Alshukairi AN, Chen R, Zhang Z, Gan M, Zhu A, Huang Y, Luo L, Mok CKP, Al Gethamy MM, Tan H, Li Z, Huang X, Li F, Sun J, Zhang Y, Wen L, Li Y, Chen Z, Zhuang Z, Zhuo J, Chen C, Kuang L, Wang J, Lv H, Jiang Y, Li M, Lin Y, Deng Y, Tang L, Liang J, Huang J, Perlman S, Zhong N, Zhao J, Malik Peiris JS, Li Y, Zhao J. Wang Y, et al. J Clin Invest. 2020 Oct 1;130(10):5235-5244. doi: 10.1172/JCI138759. J Clin Invest. 2020. PMID: 32634129 Free PMC article. Clinical Trial.
IgG responses were detected in most patients in both the severe and mild groups at 9 days after onset, and remained at a high level throughout the study. ...Anti-SARS-CoV-2 S and N IgG levels exhibited a moderate correlation with neutrali …
IgG responses were detected in most patients in both the severe and mild groups at 9 days after onset, and remai …
Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe Disease during the 2009 Influenza Pandemic in Norway.
Mohn KG, Cox RJ, Tunheim G, Berdal JE, Hauge AG, Jul-Larsen Å; Norwegian Pandemic Group, Peters B, Oftung F, Jonassen CM, Mjaaland S. Mohn KG, et al. PLoS One. 2015 Nov 25;10(11):e0143281. doi: 10.1371/journal.pone.0143281. eCollection 2015. PLoS One. 2015. PMID: 26606759 Free PMC article.
Those included were either acute hospitalized or convalescent patients with different disease severities (mild, moderate or severe). In general, protective antibody responses increased with enhanced disease severity. …
Those included were either acute hospitalized or convalescent patients with different disease severities (mil
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations.
Aleem A, Slenker AK. Aleem A, et al. 2022 May 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. 2022 May 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 34033365 Free Books & Documents.
They are considered a promising approach in managing nonhospitalized patients with mild to moderate COVID-19 who are at high risk of developing severe illness. ...Advising patients with dyspnea to seek in-person medical evaluation. Anti-SARS-CoV …
They are considered a promising approach in managing nonhospitalized patients with mild to moderate COVID-19 who are at …
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.
Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, Garcia-Valtanen P, Al-Delfi Z, Gummow J, Ferguson C, O'Connor S, Reddi BAJ, Hissaria P, Shaw D, Kok-Lim C, Gleadle JM, Beard MR, Barry SC, Grubor-Bauk B, Lynn DJ. Ryan FJ, et al. BMC Med. 2022 Jan 14;20(1):26. doi: 10.1186/s12916-021-02228-6. BMC Med. 2022. PMID: 35027067 Free PMC article.
However, despite the plethora of research on COVID-19, relatively little is known about the molecular underpinnings of these long-term effects. METHODS: We have undertaken an integrated analysis of immune responses in blood at a transcriptional, cellular, and serolo …
However, despite the plethora of research on COVID-19, relatively little is known about the molecular underpinnings of these long-term effec …
Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
Castillo-Olivares J, Wells DA, Ferrari M, Chan ACY, Smith P, Nadesalingam A, Paloniemi M, Carnell GW, Ohlendorf L, Cantoni D, Mayora-Neto M, Palmer P, Tonks P, Temperton NJ, Peterhoff D, Neckermann P, Wagner R, Doffinger R, Kempster S, Otter AD, Semper A, Brooks T, Albecka A, James LC, Page M, Schwaeble W, Baxendale H, Heeney JL. Castillo-Olivares J, et al. Front Immunol. 2021 Nov 19;12:748291. doi: 10.3389/fimmu.2021.748291. eCollection 2021. Front Immunol. 2021. PMID: 34867975 Free PMC article.
The ultimate aim of this study is to identify biomarkers of humoral immunity that could be used to differentiate severe from mild or asymptomatic SARS-CoV-2 infections. ...Our results indicate that overall, severe COVID-19 patients showed statis …
The ultimate aim of this study is to identify biomarkers of humoral immunity that could be used to differentiate severe from …
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness.
Jeewandara C, Jayathilaka D, Gomes L, Wijewickrama A, Narangoda E, Idampitiya D, Guruge D, Wijayamuni R, Manilgama S, Ogg GS, Tan CW, Wang LF, Malavige GN. Jeewandara C, et al. Sci Rep. 2021 Jan 21;11(1):2062. doi: 10.1038/s41598-021-81629-2. Sci Rep. 2021. PMID: 33479465 Free PMC article.
Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. ...During the first week of illness the NAb levels of those with mild illness was significantl
Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those wit
Evaluating And Referring Patients For Outpatient Monoclonal Antibody Therapy For Coronavirus (COVID-19) In The Emergency Department.
Aleem A, Olarewaju O, Pozun A. Aleem A, et al. 2022 May 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. 2022 May 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 34662075 Free Books & Documents.
They are considered a promising approach in managing nonhospitalized patients with mild to moderate COVID-19 who are at high risk of developing severe illness. ...Currently, the FDA has granted emergency use authorization (EUA) for clinical use of sotr …
They are considered a promising approach in managing nonhospitalized patients with mild to moderate COVID-19 who are at …
Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions.
Bonetti TCS, Latini FRM, Invitti AL, Fonseca MCM, Scorza FA, Saldanha MG, Bellucco FT, Bacarov NBS, Soane MM, Girão MJBC. Bonetti TCS, et al. Clinics (Sao Paulo). 2021 Aug 27;76:e2818. doi: 10.6061/clinics/2021/e2818. eCollection 2021. Clinics (Sao Paulo). 2021. PMID: 34468538 Free PMC article.
OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterized by high contagiousness, as well as variable clinical manifestations and immune responses. ...The antibody indexes for IgA and IgG did not differ signific …
OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterized by high contagiousness, as …
SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients.
Makatsa MS, Tincho MB, Wendoh JM, Ismail SD, Nesamari R, Pera F, de Beer S, David A, Jugwanth S, Gededzha MP, Mampeule N, Sanne I, Stevens W, Scott L, Blackburn J, Mayne ES, Keeton RS, Burgers WA. Makatsa MS, et al. Front Plant Sci. 2021 Mar 31;12:589940. doi: 10.3389/fpls.2021.589940. eCollection 2021. Front Plant Sci. 2021. PMID: 33868324 Free PMC article.
S1-specific IgG and IgA were found in saliva samples from convalescent volunteers. Conclusion: We demonstrate that recombinant SARS-CoV-2 proteins produced in plants enable robust detection of SARS-CoV-2 humoral responses. This assay can be used for seroepidemiologi …
S1-specific IgG and IgA were found in saliva samples from convalescent volunteers. Conclusion: We demonstrate that recombinant SARS-C …
30 results